非小细胞肺癌中与奥西默蒂尼布相关心脏毒性的危险因素
Yunlong Wang1, Xuan Deng1, Qinggui Qiu1
1Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Frontiers in oncology
|July 29, 2024
概括
对非小细胞肺癌 (NSCLC) 的奥西默蒂尼布治疗具有显著的心脏毒性风险. 吸烟,高脂血症,化疗和左胸部放射治疗被确定为关键的危险因素.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥西默提尼布是一种针对非小细胞肺癌 (NSCLC) 的向疗法.
- 心脏毒性是NSCLC治疗的潜在副作用之一.
- 鉴定心脏毒性风险因素对于患者管理至关重要.
研究的目的:
- 为了研究用osimertinib治疗的NSCLC患者心脏毒性风险因素.
- 为了确定心脏毒性在这个患者群体中的发生率.
主要方法:
- 一项对268名用osimertinib治疗的NSCLC患者进行的回顾性研究.
- 患者被分为心脏毒性和非心脏毒性组.
- 使用后勤回归分析来确定风险因素.
主要成果:
- 心脏毒性发生率为21.64% (268名患者中有58名).
- 显著的危险因素包括吸烟史 (OR=2.569),高脂血症 (OR=3.412),联合化疗 (OR=2.018),以及左胸部放射治疗 (OR=1.629).
结论:
- 在接受 osimertinib 的 NSCLC 患者中,心脏毒性是一个值得关注的问题.
- 吸烟史,高脂血症,并发化疗和左胸部放射治疗是奥西默提尼布诱导心脏毒性的独立危险因素.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Electron Transport Chain: Complex I and II
12.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.6K
Cancer Prevention
6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152


